HSD3B2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08420(HSD3B2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The HSD3B2 antibody targets the enzyme 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2), a critical player in steroid hormone biosynthesis. HSD3B2. encoded by the *HSD3B2* gene, is predominantly expressed in the adrenal glands, gonads, and placenta. It catalyzes the conversion of Δ5-steroids (e.g., pregnenolone, 17-hydroxypregnenolone, dehydroepiandrosterone) to Δ4-steroids (e.g., progesterone, 17-hydroxyprogesterone, androstenedione), a rate-limiting step in producing cortisol, aldosterone, and sex hormones. Dysregulation or mutations in *HSD3B2* lead to congenital adrenal hyperplasia (CAH), a disorder characterized by glucocorticoid deficiency, salt-wasting crises, and androgen excess.

HSD3B2 antibodies are essential tools in research and diagnostics. They help detect HSD3B2 protein expression in tissues, aiding in the study of steroidogenic pathways and adrenal/gonadal disorders. Clinically, these antibodies assist in confirming CAH subtypes caused by HSD3B2 mutations, which account for ~10% of CAH cases. Immunohistochemistry (IHC) and Western blotting are common applications, enabling visualization of enzyme distribution and quantification in pathological conditions.

Furthermore, HSD3B2 antibodies contribute to understanding enzyme dysfunction mechanisms, such as impaired substrate binding or catalytic activity, guiding therapeutic strategies. Their specificity ensures accurate differentiation from other isoforms (e.g., HSD3B1), which have distinct tissue expression patterns. Overall, HSD3B2 antibodies bridge molecular insights with clinical management of steroidogenesis-related diseases.